Too many white cells-TAM, JMML, or something else? Read more about Too many white cells-TAM, JMML, or something else?
Delivering intensive therapies to older adults with hematologic malignancies: strategies to personalize care. Read more about Delivering intensive therapies to older adults with hematologic malignancies: strategies to personalize care.
CAR T-cell therapy: is it prime time in myeloma? Read more about CAR T-cell therapy: is it prime time in myeloma?
The growing landscape of FLT3 inhibition in AML. Read more about The growing landscape of FLT3 inhibition in AML.
Using genomics to define pediatric blood cancers and inform practice. Read more about Using genomics to define pediatric blood cancers and inform practice.
Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy. Read more about Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy.
Biology of CNS lymphoma and the potential of novel agents. Read more about Biology of CNS lymphoma and the potential of novel agents.
Human herpesvirus-8: Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma. Read more about Human herpesvirus-8: Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma.
Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naive or refractory chronic-phase disease. Read more about Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naive or refractory chronic-phase disease.
